Annual Global Meeting of the International Gynecologic Cancer Society | Conference

Long-Lasting Benefit Observed With Atezolizumab and Bevacizumab in Recurrent Endometrial Cancer
October 03, 2022

Results from a phase 2 trial indicated that atezolizumab and bevacizumab yielded a significant duration of response in recurrent endometrial cancer.

Additional Studies Needed for Immunotherapy Combinations in Clear Cell Ovarian Carcinoma
October 03, 2022

Despite inconclusive efficacy results regarding the use of pembrolizumab plus epacadostat in patients with recurrent clear cell ovarian carcinoma, rapid accrual to the trial reveals an unmet need in this cancer subset.

David O’Malley, MD, Discusses PFS Benefit of Maintenance Rucaparib Regardless of Surgery Outcome in Newly Diagnosed Ovarian Cancer
October 01, 2022

Data from the phase 3 ATHENA-MONO study indicated that maintenance rucaparib yielded progression-free survival benefit vs placebo across all subgroups in a population of patients newly diagnosed ovarian cancer, according to David O’Malley, MD.

Quality of Life Sustained With Maintenance Olaparib Rechallenge in Platinum-Sensitive Ovarian Cancer
September 30, 2022

Patient-reported outcome data from the phase 3b OReO/ENGOT-ov38 trial showed no significant effect on quality of life following rechallenge with maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer.

Tiffany Sia, MD, Provides Rationale for Exploring Interventions for Oligoprogressive Disease in Gynecologic Malignancies Treated With ICI
September 30, 2022

At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.

First-Line Maintenance Rucaparib Achieves Longer PFS Vs Placebo in Newly Diagnosed Ovarian Cancer
September 30, 2022

Results from the phase 3 ATHENA-MONO study suggest that rucaparib could serve as a promising first-line maintenance treatment option in newly diagnosed ovarian cancer.

Dostarlimab Yields Promising Responses in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer
September 30, 2022

Patients with mismatch repair deficient, microsatellite instability–high advanced/recurrent endometrial cancer may derive benefit from treatment with dostarlimab-gxly.

Durvalumab Plus CRT Fails to Meet PFS End Point in High-Risk Locally Advanced Cervical Cancer
September 30, 2022

Results from the phase 3 CALLA trial indicated that durvalumab in combination with chemoradiotherapy did not yield a meaningful improvement in progression-free survival compared with chemoradiotherapy alone in high-risk locally advanced cervical cancer.

Measure of CA-125 Elimination May Guide Interval Debulking Surgery Selection in High-Grade Serous Ovarian Cancer
September 29, 2022

Results from a Korean study presented at 2022 IGCS showed that the level of CA-125 at different timepoints during neoadjuvant chemotherapy may help clinicians decide which patients with high-grade serous ovarian cancer should undergo interval debulking surgery.